Beta Bionics, Inc.

NASDAQ:BBNX

Medical - Equipment & Services

Healthcare
$14.33 +3.18%

+$0.42 today

Market cap
$644.70M
Beta
3.39
P/E (TTM)
-9.1
EPS (TTM)
-$1.50
52W Low $8.80High $32.71

Volume 1.38M

Average 0.99M

BBNX Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Beta Bionics, Inc.NASDAQ: BBNX

Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other current liabilities rises 14.0% from a year ago

Other current liabilities stood at $8.34M at the end of Q1 FY2026, up 14.0% from a year earlier and down 42.8% from the prior quarter. Over 3 fiscal years it compounded at +122.5% a year.

Context

  • Other current liabilities amounted to 2.7% of total assets at the end of Q1 FY2026, up 0.6 pp from a year earlier.
  • Other current liabilities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other current liabilities keeps rising in the next quarterly balance sheet after a +14.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.34M-42.8% QoQ
Last fiscal yearDec 2025
$14.59M+33.4% YoY
Year agoMar 2025
$7.32M+14.0% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.0%——
1 year+33.4%——
3-year CAGR+122.5%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
14.59M USD
Year-over-year change
+33.4%
3-year CAGR
+122.5%

Other Current Liabilities vs competitors

How BBNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +14.0% is the 4th highest of 7, against a peer median of +60.2%.
  • Other current liabilities amounts to 2.7% of total assets for BBNX, versus a peer median of 8.7%.
BBNX Competitors
Other Current Liabilities for BBNX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVONovo Nordisk A/SJun 2026DKK 45.5B DKK-69.8%+21.9%7.6%
DXCMDexCom, Inc.Jun 2026$1.9B USD+3302.7%+4.6%29.5%
MMEDMiniMed Group, Inc. Common StockJul 2026$488M USD——10.3%
TNDMTandem Diabetes Care, Inc.Mar 2026$139.8M USD-1.7%+28.9%12.1%
MNKDMannKind CorporationMar 2026$64.98M USD+122.2%+61.9%8.7%
BBNXBeta Bionics, Inc.Mar 2026$8.34M USD+14.0%+122.5%2.7%
ORMPOramed Pharmaceuticals Inc.Mar 2026$3.23M USD+286.1%—1.2%
PODDInsulet CorporationJun 2026$0 USD-100.0%+23.5%0.0%
Peer median (excluding BBNX) —+60.2%+23.5%8.7%

Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents27.68M26.57M30.43M31.58M
Short-term Investments070.18M73.14M187.55M
Net Receivables04.45M12M19.89M
Inventory01.25M13.32M21.72M
Other Current Assets250K275K1.05M100K
Total Current Assets28.47M103.62M132.92M267.91M
Property, Plant & Equipment (Net)6.87M6.2M11.42M15.23M
Goodwill0000
Intangible Assets0000
Long-term Investments00045.43M
Tax Assets0000
Other Non-current Assets193K221K5.3M180K
Total Non-current Assets7.06M6.42M16.72M60.84M
Total Assets35.53M110.04M149.65M328.74M
Account Payables430K1.17M2.85M5M
Short-term Debt0000
Tax Payables0000
Deferred Revenue087K939K1.56M
Other Current Liabilities1.32M1.14M10.94M14.59M
Total Current Liabilities8.87M10.61M21.15M30.92M
Long-term Debt0000
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0255K1.86M3.3M
Other Non-current Liabilities10.5M37.83M44.9M1.55M
Total Non-current Liabilities13.65M40.83M52.48M10.21M
Total Liabilities22.53M51.43M73.63M41.13M
Common Stock1K1K1K4K
Retained Earnings(185.57M)(229.66M)(296.74M)(369.94M)
Accumulated OCI0137K65K403K
Other Stockholders Equity0000
Minority Interest0000
Total Equity13M58.61M76.01M287.61M
Total Debt4.13M4.22M7.26M7.3M
Net Debt(23.54M)(22.34M)(23.18M)(24.27M)

Beta Bionics, Inc.

NASDAQ:BBNX

Intrinsic Alpha fair value

Locked

Current Price

$14.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.